EP4055005A4 - Flüssige melphalanzusammensetzung - Google Patents

Flüssige melphalanzusammensetzung Download PDF

Info

Publication number
EP4055005A4
EP4055005A4 EP20886165.8A EP20886165A EP4055005A4 EP 4055005 A4 EP4055005 A4 EP 4055005A4 EP 20886165 A EP20886165 A EP 20886165A EP 4055005 A4 EP4055005 A4 EP 4055005A4
Authority
EP
European Patent Office
Prior art keywords
melphalant
composition
liquid
melphalant composition
liquid melphalant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20886165.8A
Other languages
English (en)
French (fr)
Other versions
EP4055005A1 (de
Inventor
Nimitt CHOKSHI
Rushabh Shah
Nagnath G GOBADE
Kamal Kumar Upadhyay
Alex K George
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intas Pharmaceuticals Ltd
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of EP4055005A1 publication Critical patent/EP4055005A1/de
Publication of EP4055005A4 publication Critical patent/EP4055005A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/44—Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP20886165.8A 2019-11-04 2020-11-04 Flüssige melphalanzusammensetzung Pending EP4055005A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921044683 2019-11-04
PCT/IB2020/060334 WO2021090183A1 (en) 2019-11-04 2020-11-04 Liquid melphalan composition

Publications (2)

Publication Number Publication Date
EP4055005A1 EP4055005A1 (de) 2022-09-14
EP4055005A4 true EP4055005A4 (de) 2023-11-29

Family

ID=75849601

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20886165.8A Pending EP4055005A4 (de) 2019-11-04 2020-11-04 Flüssige melphalanzusammensetzung

Country Status (2)

Country Link
EP (1) EP4055005A4 (de)
WO (1) WO2021090183A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116283627A (zh) * 2023-01-13 2023-06-23 深圳市江川医药技术有限公司 一种美法仑杂质g的合成方法
CN116102444A (zh) * 2023-01-16 2023-05-12 深圳振强生物技术有限公司 一种美法仑杂质d的纯化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2060031C1 (ru) * 1993-05-27 1996-05-20 Онкологический научный центр Способ получения сарколизина для внутривенных инъекций

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020363B2 (en) * 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
MX388477B (es) * 2009-05-29 2025-03-12 Cydex Pharmaceuticals Inc Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de fabricación y uso de las mismas.
US10537520B2 (en) * 2015-06-30 2020-01-21 Leiutis Pharmaceuticals Pvt. Ltd. Stable liquid formulations of melphalan
WO2017085696A1 (en) * 2015-11-20 2017-05-26 Leiutis Pharmaceuticals Pvt Ltd Parenteral formulations of melphalan

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2060031C1 (ru) * 1993-05-27 1996-05-20 Онкологический научный центр Способ получения сарколизина для внутривенных инъекций

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVID Q. MA ET AL: "Comparative effects of (SBE)7m-?-CD and HP-?-CD on the stability of two anti-neoplastic agents, melphalan and carmustine", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 89, no. 2, 1 February 2000 (2000-02-01), pages 275 - 287, XP055200060, ISSN: 0022-3549, DOI: 10.1002/(SICI)1520-6017(200002)89:2<275::AID-JPS15>3.0.CO;2-C *
See also references of WO2021090183A1 *

Also Published As

Publication number Publication date
WO2021090183A1 (en) 2021-05-14
EP4055005A1 (de) 2022-09-14

Similar Documents

Publication Publication Date Title
EP3823584A4 (de) Reinigungsmittelzusammensetzung
DK3924443T3 (da) Compositions
DK3496551T3 (da) Flydende allulosesammensætning
DK3558278T3 (da) Flydende cannabinoidsammensætning
EP3816254A4 (de) Haftzusammensetzung
EP3825377A4 (de) Klebstoffzusammensetzung
EP3871694A4 (de) Zusammensetzung
EP3862407A4 (de) Klebstoffzusammensetzung
EP3816252A4 (de) Haftzusammensetzung
DK3840596T3 (da) Sammensætning
EP3825378A4 (de) Klebstoffzusammensetzung
EP3819351A4 (de) Klebstoffzusammensetzung
EP4079787A4 (de) Härtbare zusammensetzung
EP3981256A4 (de) Zusammensetzung
EP3897866C0 (de) Antimikrobielle zusammensetzung
EP3715431A4 (de) Haftzusammensetzung
EP3766948A4 (de) Schmierölzusammensetzung
PT3765379T (pt) Composições
EP3941942A4 (de) Zusammensetzung
EP4079788A4 (de) Härtbare zusammensetzung
EP3756700A4 (de) Flüssige emboliemittelzusammensetzung
EP3954721A4 (de) Zusammensetzung
EP3741814C0 (de) Zusammensetzung
EP3826606A4 (de) Flüssige duftstoffzusammensetzungen
EP3829532A4 (de) Keratinzusammensetzungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231027

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/198 20060101ALI20231023BHEP

Ipc: A61K 47/20 20060101ALI20231023BHEP

Ipc: A61K 47/12 20060101ALI20231023BHEP

Ipc: A61K 47/10 20170101ALI20231023BHEP

Ipc: A61K 47/02 20060101ALI20231023BHEP

Ipc: A61P 35/00 20060101ALI20231023BHEP

Ipc: A61K 9/08 20060101ALI20231023BHEP

Ipc: C07C 229/36 20060101AFI20231023BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250314